Zymergen Reports Preliminary First Quarter 2022 Financial Results

Rhea-AI Summary

Zymergen reported preliminary financial results for Q1 2022, with total revenue reaching $4.8 million, largely from R&D service agreements and collaborations. However, the company faced significant challenges, posting total operating expenses of $68.4 million and a net loss of $72.1 million during the quarter. As of March 31, 2022, Zymergen held $337.0 million in cash and cash equivalents. The results, while preliminary and unaudited, may change upon finalization.

A conference call will be held on May 12, 2022, to discuss these results.

Positive

• Total revenue of $4.8 million from R&D service agreements and collaborations.

Negative

• Net loss of $72.1 million in Q1 2022.
• Total operating expenses of $68.4 million, indicating high financial strain.
• Preliminary results are subject to significant change, which may affect investor confidence.

EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Biotechnology company Zymergen Inc. (“Zymergen” or the “Company”), today reported preliminary financial results for the first quarter ended March 31, 2022.

“Our mission at Zymergen is to partner with nature to make better products, a better way, for a better world. One of the key transformations we have made is to create a nimble, disciplined product development process,” said Zymergen’s interim CEO, Jay Flatley. “We now have the infrastructure to support great execution and the delivery of products across our three businesses of Advanced Materials, Drug Discovery and Automation.”

Preliminary First Quarter 2022 Financial Results
Total revenue for the first quarter of 2022 was $4.8 million, primarily relating to R&D service agreements and collaboration revenue.

Total operating expenses, including cost of revenue, for the first quarter of 2022 were $68.4 million.

Net loss in the first quarter of 2022 was $72.1 million.

Cash and cash equivalents were $337.0 million as of March 31, 2022, excluding restricted cash of $11.5 million.

The financial results presented in this press release are preliminary and unaudited. They are subject to the completion and finalization of Zymergen’s financial and accounting closing procedures. They reflect management’s estimates based solely upon information available to management as of the date of this press release. Further information learned during that completion and finalization may alter the final results. In addition, the preliminary results should not be viewed as a substitute for full quarter financial statements prepared in accordance with GAAP. There is a possibility that Zymergen’s first quarter financial results could vary materially from these preliminary results. Accordingly, you should not place undue reliance upon this preliminary information.

Webcast Information
Zymergen will host a conference call to discuss the preliminary first quarter 2022 financial results after market close on Thursday, May 12, 2022, at 1:30 pm Pacific Time / 4:30 pm Eastern Time. A webcast of the conference call can be accessed at https://investors.zymergen.com/

About Zymergen
Zymergen is a biotech company that designs and produces molecules, microbes and materials for diverse end markets. We partner with nature to make better products, a better way, for a better world.

Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on the Company’s beliefs and assumptions and on information currently available to it on the date of this press release. In some cases, you can identify these statements by forward-looking words such as “may,” “will,” “continue,” “anticipate,” “intend,” “could,” “project,” “expect” or the negative or plural of these words or similar expressions. Forward-looking statements in this press release, include but are not limited to statements regarding the Company’s preliminary financial results, the Company’s strategy of pursuing continuous launches of breakthrough products, the customer pipeline for our automation business, the potential benefits of our new product development process and our expectations for future operating expenses. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements, including, but not limited to, risks relating to the Company’s ability to successfully commercialize or generate revenue from its products; the Company’s ability to execute on its new strategic plan; the Company’s ability to identify commercial opportunities; the Company’s ability to attract automation customers; the effectiveness and rigor of the Company’s phase gates and product evaluation process; the Company’s ability to reduce its operating costs and extend its cash runway; and material differences between the Company’s actual financial results and the preliminary financial results presented herein. These and other risks are described more fully in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, and other documents the Company subsequently files with the SEC, including the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contact
investors@zymergen.com

PRELIMINARY CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
(unaudited)

	Three Months Ended  March 31,
	2022				2021
Revenue	$	4,791			$	3,735
Operating expenses:
Cost of service revenue		12,455				21,130
Research and development		28,739				39,811
Sales and marketing		3,638				6,872
General and administrative		23,705				19,331
Restructuring charges		(130	)			—
Total operating expenses		68,407				87,144
Loss from operations		(63,616	)			(83,409	)
Other income (expense):
Interest income		51				43
Interest and other expense		(8,577	)			(1,211	)
Total other expense		(8,526	)			(1,168	)
Loss before income taxes		(72,142	)			(84,577	)
Benefit from (provision for) income taxes		26				(8	)
Net loss	$	(72,116	)		$	(84,585	)
Net loss per share attributable to common stockholders, basic	$	(0.70	)		$	(6.51	)
Net loss per share attributable to common stockholders, diluted	$	(0.70	)		$	(6.51	)
Weighted-average shares used in computing net loss per share to common stockholders, basic		103,109,168				12,996,344
Weighted-average shares used in computing net loss per share to common stockholders, diluted		103,109,168				13,340,457

PRELIMINARY CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)

	As of March 31, 2022			As of December 31, 2021
ASSETS
Current assets:
Cash and cash equivalents	$	336,980		$	386,105
Accounts receivable, billed and unbilled		2,399			3,085
Inventory		5,995			6,035
Other current assets		8,241			12,124
Total current assets		353,615			407,349
Property and equipment, net		56,004			53,799
Right-of-use assets		147,960			—
Goodwill		40,645			40,645
Intangible assets, net		7,929			8,529
Other assets		12,036			12,074
Total assets	$	618,189		$	522,396
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable, accrued and other liabilities	$	27,754		$	22,914
Short-term operating lease liabilities		7,285			—
Short-term debt, net		50,560			43,953
Other current liabilities		2,862			6,686
Total current liabilities		88,461			73,553
Long-term operating lease liabilities		181,168			—
Other long-term liabilities		4,496			40,357
Total liabilities		274,125			113,910
Total stockholders' equity		344,064			408,486
Total liabilities and stockholders' equity	$	618,189		$	522,396

 

FAQ

What were Zymergen's total revenues for Q1 2022?

Zymergen reported total revenues of $4.8 million for Q1 2022.

What was Zymergen's net loss for the first quarter of 2022?

The net loss for Zymergen in Q1 2022 was $72.1 million.

What are Zymergen's operating expenses in Q1 2022?

Zymergen's operating expenses totaled $68.4 million in Q1 2022.

What is Zymergen's cash position as of March 31, 2022?

As of March 31, 2022, Zymergen had cash and cash equivalents of $337.0 million.

When will Zymergen discuss their Q1 2022 financial results?

Zymergen will host a conference call to discuss the Q1 2022 results on May 12, 2022.